Drug targeting to cancer by nanoparticles surface functionalized with special biomolecules

Current Medicinal Chemistry

Volumn 19, Issue 19, 2012, Pages 3188-3195

  Holgado, M A ^a   Martin Banderas L ^a   Alvarez Fuentes J ^a   Fernandez Arevalo M ^a   Arias, J L ^b  

^a UNIVERSITY OF SEVILLE   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Active drug targeting; Cancer; EPR effect; Ligand mediated delivery; Multi drug resistance; Nanoparticle; Passive drug targeting

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; ARGINYLGLYCYLASPARTIC ACID; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLIC ACID; GLYCOPROTEIN P; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; NANOCARRIER; PACLITAXEL; POLYSACCHARIDE; POVIDONE; SMALL INTERFERING RNA; STARCH; TAMOXIFEN; TRANSFERRIN;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER RESISTANCE; CANCER TISSUE; CHEMICAL MODIFICATION; DRUG COATING; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG UPTAKE; HUMAN; HYDROPHILICITY; LIPOSOMAL DELIVERY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; SURFACE PROPERTY;

ANIMALS; BIOLOGICAL TRANSPORT; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS;

EID: 84863666147     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800784720     Document Type: Review

References (116)

1. Arias, J.L. Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery systems. Molecules, 2008, 13, 2340-2369.
2. Davis, M.E.; Chen, Z.; Shin, D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Dicov., 2008, 7, 771-782.
3. Reddy, L.H.; Couvreur, P. Novel approaches to deliver gemcitabine to cancers. Curr. Pharm. Design, 2008, 14, 1124-1137.
4. Cho, K.; Wang, X.; Nie, S.; Chen, Z.; Shin, D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res., 2008, 14, 1310-1316.
5. Arias, J.L.; Reddy, L.H.; Couvreur, P. Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine. J. Drug Target., 2009, 17, 586-598.
6. Arias, J.L.; Reddy, L.H.; Couvreur, P. Superior preclinical efficacy of gemcitabine developed as chitosan nanoparticulate system. Biomacromolecules, 2011, 12, 97-104.
7. Couvreur, P; Vauthier, C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res., 2006, 23, 1417-1450.
8. Gu, F.X.; Karnik, R.; Wang, A.Z.; Alexis, F.; Levy-Nissenbaum, E.; Hong, S.; Langer, R.S.; Farokhzad, O.C. Targeted nanoparticles for cancer therapy. Nano Today, 2007, 2, 14-21.
9. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev., 2002, 54, 631-651.
10. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev., 2001, 53, 283-318.
11. Arias, J.L. Drug targeting strategies in cancer treatment: an overview. Mini Rev. Med. Chem., 2011, 11, 1-17.
12. Wagner, S.; Rothweiler, F.; Anhorn, M.G.; Sauer, D.; Riemann, I.; Weiss, E.C.; Katsen-Globa, A.; Michaelis, M.; Cinatl, J.; Schwartz, D.; Kreuter, J.; von Briesen, H.; Langer, K. Enhanced drug targeting by attachment of an anti alpha v integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials, 2010, 31, 2388-2398.
13. Min, K.; Jo, H.; Song, K.; Cho, M.; Chun, Y.S.; Jon, S.; Kim, W.J.; Ban, C. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers. Biomaterials, 2011, 32, 2124-2132.
14. Maeda, H.; Bharate, G.Y.; Daruwalla, J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm., 2009, 71, 409-419.
15. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev., 2011, 63, 136-51.
16. Patil, Y.B.; Toti, U.S.; Khdair, A.; Ma, L.; Panyam, J. Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. Biomaterials, 2009, 30, 859-866.
17. Bibby, D.C.; Talmadge, J.E.; Dalal, M.K.; Kurz, S.G.; Chytil, K.M.; Barry, S.E.; Shand, D.G.; Steiert, M. Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. Int. J. Pharm., 2005, 293, 281-290.
18. Karmali, P.P.; Kotamraju, V.R.; Kastantin, M.; Black, M.; Missirlis, D.; Tirrell, M.; Ruoslahti, E. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine, 2009, 5, 73-82.
19. Wang, X.L.; Chen, D.X.; Pei, H.; Cai, L.; Zhao, X.; Wei, Y.; Chen, L. Truncated bFGF-mediated cationic liposomal paclitaxel for tumor-targeted drug delivery: improved pharmacokinetics and biodistribution in tumor-bearing mice. J. Pharm. Sci., 2011, 100, 1196-1205.
20. Zhang, Z.; Chen, J.; Ding, L.; Jin, H.; Lovell, J.F.; Corbin, L.R.; Cao, W.; Lo, P.C.; Yang, M.; Tsao, M.S.; Luo, Q.; Zheng, G. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small, 2010, 6, 430-437.
21. Garg, A.; Tisdale, A.W.; Haidari, E.; Kokkoli, E. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int. J. Pharm., 2009, 366, 201-210.
22. Mai, J.; Song, S.; Rui, M.; Liu, D.; Ding, Q.; Peng, J.; Xu, Y. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells. J. Control. Release, 2009, 139, 174-181.
23. Farokhzad, O.C.; Cheng, J.; Teply, B.A.; Sherifi, I.; Jon, S.; Kantoff, P.W.; Richie, J.P.; Langer, R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA, 2006, 103, 6315-6320.
24. Liang, B.; He, M.L.; Chan, C.Y.; Chen, Y.C.; Li, X.P.; Li, Y.; Zheng, D.; Lin, M.C.; Kung, H.F.; Shuai, X.T.; Peng, Y. The use of folate-PEG-grafted- hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat. Biomaterials, 2009, 30, 4014-4020.
25. Durán, J.D.G.; Arias, J.L.; Gallardo, V.; Delgado, A.V. Magnetic colloids as drug vehicles. J. Pharm. Sci., 2008, 97, 2948-2983.
26. Moghimi, S.M.; Szebeni, J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res., 2003, 42, 463-478.
27. Park, J.W. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res., 2002, 4, 95-99.
28. Gref, R.; Luck, M.; Quellec, P.; Marchand, M.; Dellacherie, E.; Harnisch, S.; Blunk, T.; Müller, R.H. "Stealth" corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B Biointerfaces, 2000, 18, 301-313.
29. Shang, H.; Chang, W.S.; Kan, S.; Majetich, S.A.; Lee, G.U. Synthesis and characterization of paramagnetic microparticles through emulsion-templated free radical polymerization. Langmuir, 2006, 22, 2516-2522.
30. Wang, M.; Thanou, M. Targeting nanoparticles to cancer. Pharm. Res., 2010, 62, 90-99.
31. Portet, D.; Denizot, B.; Rump, E.; Rump, E.; Lejeune, J.J.; Jallet, P. Nonpolymeric coatings of iron oxide colloids for biological use as magnetic resonance imaging contrast agents. J. Colloid Interface Sci., 2001, 238, 37-42.
32. Fauconnier, N.; Pons, J.N.; Roger, J.; Bee, A. Thiolation of maghemite nanoparticles by dimercaptosuccinic acid. J. Colloid Interface Sci., 1997, 194, 427-433.
33. Zhang, C.; Wangler, B.; Morgenstern, B.; Zentgraf, H.; Eisenhut, M.; Untenecker, H.; Kruger, R.; Huss, R.; Seliger, C.; Semmler, W.; Kiessling, F. Silica-and alkoxysilane-coated ultrasmall superparamagnetic iron oxides particles: a promising tool to label cells for magnetic resonance imaging. Langmuir, 2007, 23, 1427-1434.
34. Mitra, S.; Gaur, U.; Gosh, P.C.; Maitra, A.N. Tumor targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J. Control. Release, 2001, 74, 317-323.
35. Huwyler, J.; Drewe, J.; Krähenbühl, S. Tumor targeting using liposomal antineoplastic drugs. Int. J. Nanomedicine, 2008, 3, 21-29.
36. Decuzzi, P.; Pasqualini, R.; Arap, W.; Ferrari, M. Intravascular delivery of particulate systems: does geometry really matter?. Pharm. Res., 2009, 26, 235-243.
37. Etame, A.B.; Smith, C.A.; Chan, W.; Rutka, J.T. Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature. Nanomedicine, 2011, 7, 992-1000.
38. Li, Y.; Wang, J.; Wientjes, M.G.; Au, J. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv. Drug Deliv. Rev., 2011, doi:10.1016/j.addr.2011.04.006.
39. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev., 2011, 63, 136-151.
40. Hau, P.; Fabel, K.; Baumgart, U.; Rummele, P.; Grauer, O.; Bock, A.; Dietmaier, C.; Dietmaier, W.; Dietrich, J.; Dudel, C.; Hübner, F.; Jauch, T.; Drechsel, E.; Kleiter, I.; Wismeth, C.; Zellner, A.; Brawanski, A.; Steinbrecher, A.; Marienhagen, J.; Bogdahn, U. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer, 2004, 100, 1199-1207.
41. Yoshizawa, Y.; Kono, Y.; Ogawara, K.; Kimura, T.; Higaki, K. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int. J. Pharm., 2011, 412, 132-141.
42. Shenoy, D.B.; Amiji, M.M. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int. J. Pharm., 2005, 293, 261-270.
43. Zara, G.P.; Cavalli, R.; Bargoni, A.; Fundaro, A.; Vighetto, D.; Gasco, M.R. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J. Drug Target., 2002, 10, 327-335.
44. Allen, T.M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Sci., 1994, 15, 215-220.
45. Park, J.W.; Kirpotin, D.B.; Hong, K.; Shalaby, R.; Shao, Y.; Nielsen, U.B.; Marks, J.D.; Papahadjopoulus, D.; Benz, C.C. Anti-HER2 immunoliposomes: enhanced anticancer efficacy due to targeted delivery. J. Control. Release, 2001, 74, 95-113.
46. Park, J.W.; Hong, K.; Kirpotin, D.B.; Colbern, G.; Shalaby, R.; Baselga, J.; Shao, Y.; Nielsen, U.B.; Marks, J.D.; Moore, D.; Papahadjopoulus, D.; Benz, C.C. Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin. Cancer Res., 2002, 8, 1172-1181.
47. Hood, J.D.; Bednarski, M.; Frausto, R.; Guccione, S.; Reisfeld, R.A.; Xiang, R.; Cheresh, D.A. Tumor regression by targeted gene delivery to the neovasculature. Science, 2002, 296, 2404-2407.
48. Xu, S.L.; Liu, Y.; Tai, H.C.; Zhu, J.; Ding, H.; Lee, R.J. Synthesis of transferrin (Tf) conjugated liposomes via Staudinger ligation. Int. J. Pharm., 2011, 404, 205-210.
49. Li, J.L.; Wang, L.; Liu, X.Y.; Zhang, Z.P.; Guo, H.C.; Liu, W.M.; Tang, S.H. In vitro cancer cell imaging and therapy using transferrin-conjugated gold nanoparticles. Cancer Lett., 2009, 274, 319-326.
50. Sudhagar, S.; Sathya, S.; Pandian, K.; Lakshmi, B.S. Targeting and sensing cancer cells with ZnO nanoprobes in vitro. Biotechnol. Lett., 2011, 33, 1891-1896.
51. Stella, B.; Arpicco, S.; Peracchia, M.T.; Desmaële, D.; Hoebeke, J.; Rendir, M.; d́Angelo, J.; Cattel, L.; Couvreur, P. Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci., 2000, 89, 1452-1464.
52. Park, E.K.; Lee, S.B.; Lee, Y.M. Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. Biomaterials, 2005, 26, 1053-1061.
53. Jeong, Y.I.; Seo, S.J.; Park, I.K.; Lee, H.C.; Kang, I.C.; Akaike, T.; Cho, C.S. Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly(gamma-benzyl L-glutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety. Int. J. Pharm., 2005, 296, 151-161.
54. Önyüksel, H.; Mohantya, P.S.; Rubinsteina, I. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer. Int. J. Pharm., 2009, 365, 157-161.
55. Jain, A.; Chasoo, G.; Singh, S.K.; Saxena, A.K.; Jain, S.K. Transferrin-appended PEGylated nanoparticles for temozolomide delivery to brain: in vitro characterisation. J. Microencapsul., 2011, 28, 21-28.
56. Gan, C.W.; Feng, S.S. Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials, 2010, 31, 7748-7757.
57. Hallahan, D.; Geng, L.; Qu, S.; Scarfone, C.; Giorgio, T.; Donnelly, E.; Gao, X.; Clanton, J. Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell, 2003, 3, 63-74.
58. Schiffelers, R.M.; Koning, G.A.; ten Hagen, T.L.; Fens, M.H.; Schraa, A.J.; Janssen, A.P.; Kok, R.J.; Molema, G.; Strom, G. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Release, 2003, 91, 115-122.
59. Costantino, L.; Gandolfi, F.; Tosi, G.; Rivasi, F.; Vandelli, M.A.; Forni, F. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J. Control. Release, 2005, 108, 84-96.
60. Taratula, O.; Garbuzenko, O.B.; Kirkpatrick, P.; Pandya, I.; Savla, R.; Pozharov, V.P.; He, H.; Minko, T. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J. Control. Release, 2009, 140, 284-293.
61. Veiseh, O.; Kievit, F.M.; Gunn, J.W.; Ratner, B.D.; Zhang, M. A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells. Biomaterials, 2009, 30, 649-657.
62. Guan, H.; McGuire, M.J.; Li, S.; Brown, K.C. Peptide-targeted polyglutamic acid doxorubicin conjugates for the treatment of alpha(v)beta(6)-positive cancers. Bioconjug. Chem., 2008, 19, 1813-1821.
63. Ko, H.Y.; Choi, K.J.; Lee, C.H.; Kim, S. A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin αvβ3 and tenascin-C proteins. Biomaterials, 2011, 32, 1130-1138.
64. Pissuwan, D.; Niidome, T.; Cortie, M.B. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J. Control. Release, 2011, 149, 65-71.
65. Willis, M.C.; Collins, B.D.; Zhang, T.; Green, L.S.; Sebesta, D.P.; Bell, C.; Kellogg, E.; Gill, S.C.; Magallanez, A.; Knauer, S.; Bendele, R.A.; Gill, P.S.; Janjic, N.; Collins, B. Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug. Chem., 1998, 9, 573-582.
66. Levy-Nissenbaum, E.; Radovic-Moreno, A.F.; Wang, A.Z.; Langer, R.; Farokhzad, O.C. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol., 2008, 26, 442-449.
67. Imai, K.; Takaoka, A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer, 2006, 6, 714-727.
68. Kos, J.; Obermajer, N.; Doljaka, B.; Kocbeka, P.; Kristl, J. Inactivation of harmful tumour-associated proteolysis by nanoparticulate system. Int. J. Pharm., 2009, 381, 106-112.
69. Sun, B.; Ranganathan, B.; Feng, S.S. Multifunctional poly(D, L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials, 2008, 29, 475-486.
70. Heister, E.; Neves, V.; Tilmaciu, C.; Lipert, K.; Beltran, V.; Coley, H.M.; Silva, S.R.P.; McFadden, J. Triple functionalisation of single-walled carbon nanotubes with doxorubicin, a monoclonal antibody, and a fluorescent marker for targeted cancer therapy. Carbon, 2009, 47, 2152-2160.
71. Sapra, P.; Allen, T.M. Ligand-targeted liposomal anticancer drugs. Prog. Lipid Res., 2003, 42, 439-462.
72. Maruyama, K.; Takizawa, T.; Yuda, T.; Kennel, S.J.; Huang, L.; Iwatsuru, M. Targetability of novel immunoliposomes modified with amphipatic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal-antibodies. Biochim. Biophys. Acta, 1995, 1234, 74-80.
73. Gao, J.; Zhonga, W.; Hea, J.; Li, H.; Zhanga, H.; Zhoua, G.; Li, B.; Lua, Y.; Zoua, H.; Koua, G.; Zhanga, D.; Wanga, H.; Guoa, Y.; Zhong, Y. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes. Int. J. Pharm., 2009, 374, 145-152.
74. Zhang, Y.; Schlachetzki, F.; Pardridge, W.M. Global non-viral gene transfer to the primate brain following intravenous administration. Mol. Ther., 2003, 7, 11-18.
75. Sahoo, S.K.; Ma, W.; Labhasetwar, V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int. J. Cancer, 2004, 112, 335-340.
76. Han, L.A.; Huang, R.Q.; Li, J.F.; Liu, S.H.; Huang, S.X.; Jiang, C. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer. Biomaterials, 2011, 4, 1242-1252.
77. Huang, R.K.; Steinmetz, N.F.; Fu, C.Y.; Manchester, M.; Johnson, J.E. Transferrin-mediated targeting of bacteriophage HK97 nanoparticles into tumor cells. Nanomedicine (Lond), 2011, 6, 55-68.
78. Zhai, G.X.; Wu, J.; Yu, B.; Guo, C.Y.; Yang, X.G.; Lee, R.J. A transferrin receptor-targeted liposomal formulation for docetaxel. J. Nanosci. Nanotechnol., 2010, 10, 5129-5136.
79. Zeng, X.; Sun, Y.X.; Qu, W.; Zhang, X.Z.; Zhuo, R.X. Biotinylated transferrin/avidin/biotinylated disulfide containing PEI bioconjugates mediated p53 gene delivery system for tumor targeted transfection. Biomaterials, 2010, 31, 4771-4780.
80. Zheng, Y.; Yu, B.; Weecharangsan, W.; Piao, L.; Darby, M.; Mao, Y.C.C.; Koynova, R.; Yang, X.J.; Li, H.; Xu, S.L.; Lee, L.J.; Sugimoto, Y.; Brueggemeier, R.W.; Lee, R.J. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7 alpha-APTADD to breast cancer cells. Int. J. Pharm., 2010, 390, 234-241.
81. Ferris, D.P.; Lu, J.; Gothard, C.; Yanes, R.; Thomas, C.R.; Olsen, J.C.; Stoddart, J.F.; Tamanoi, F.; Zink, J.I. Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Small, 2011, 7, 1816-1826.
82. He, H.; Li, Y.; Jia, X.R.; Du, J.; Ying, X.; Lu, W.L.; Lou, J.N.; Wei, Y. PEGylated poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials, 2011, 32, 478-487.
83. Sahoo, S.K.; Labhasetwar, V. Enhanced antiproliferative activity of transferrin conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol. Pharm., 2005, 2, 373-383.
84. Derycke, A.; Kamuhabwa, A.; Gijsens, A.; Roskams, T.; de Vos, D.; Kasran, A.; Huwyler, J.; Missiaen, L.; de Witte, P.A.M. Transferrin-conjugated liposome targeting of the photosensitizer AlPcS4 to rat bladder carcinoma cells. J. Natl. Cancer Inst., 2004, 96, 1620-1630.
85. Hwang, S.H.; Rait, A.; Pirollo, K.F.; Zhou, Q.; Yenugonda, V.M.; Chinigo, G.M.; Brown, M.L.; Chang, E.H. Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue. Mol. Cancer. Ther., 2008, 7, 559-568.
86. Garcia-Bennett, A.; Nees, M.; Fadeel, B. In search of the Holy Grail: folate-targeted nanoparticles for cancer therapy. Biochem. Pharmacol., 2011, 81, 976-984.
87. Ulbrich, K.; Michaelis, M.; Rothweiler, F.; Knobloch, T.; Sithisarn, P.; Cinatl, J.; Kreuter, J. Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells. Int. J. Pharm., 2011, 406, 128-134.
88. Esmaeili, F.; Grahremani, M.H.; Ostad, S.N.; Atyabi, F.; Seyedabadi, M.; Malekshahi, M.R.; Amini, M.; Dinarvand, R. Folate-receptor-targeting delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J. Drug Target., 2008, 16, 415-423.
89. Kim, S.H.; Jeong, J.H.; Chun, K.W.; Park, T.G. Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir, 2005, 21, 8852-8857.
90. Stevens, P.J.; Sekido, M.; Lee, R.J. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. Pharm. Res., 2004, 21, 2153-2157.
91. Bothun, G.D.; Lelis, A.; Chen, Y.; Scully, K.; Anderson, L.E.; Stoner, M.A. Multicomponent folate-targeted magnetoliposomes: design, characterization, and cellular uptake. Nanomedicine, 2011, 7, 797-805.
92. Lai, T.Y.; Lee, W.C. Killing of cancer cell line by photoexcitation of folic acid-modified titanium dioxide nanoparticles. J. Photochem. Photobiol. A Chem., 2009, 204, 148-153.
93. Pan, J.; Feng, S.S. Targeting and imaging cancer cells by folate-decorated, quantum dots (QDs)-loaded nanoparticles of biodegradable polymers. Biomaterials, 2009, 30, 1176-1183.
94. Guo, M.; Que, C.; Wang, C.; Liu, X.; Yan, H.; Liu, K. Multifunctional superparamagnetic nanocarriers with folate-mediated and pH-responsive targeting properties for anticancer drug delivery. Biomaterials, 2011, 32, 185-194.
95. Shmeeda, H.; Mak, L.; Tzemach, D.; Astrahan, P.; Tarshish, M.; Gabizon, A. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol. Cancer Ther., 2006, 5, 818-824.
96. Pan, X.Q.; Lee, R.J. In vivo antitumor activity of folate receptor-targeted liposomal daunorubicin in a murine leukemia model. Anticancer Res., 2005, 25, 343-346.
97. Goren, D.; Horowitz, A.T.; Tzemach, D.; Tarshish, M.; Zalipsky, S.; Gabizon, A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res., 2000, 6, 1949-1957.
98. Zhang, C.; Zhao, L.Q.; Dong, Y.F.; Zhang, X.Y.; Lin, J.; Chen, Z. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery. Eur. J. Pharm. Biopharm., 2010, 76, 10-16.
99. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev., 2002, 2, 48-58.
100. Jabr-Milane, L.S.; van Vlerken, L.E.; Yadav, S.; Amiji, M.M. Multifunctional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev., 2008, 34, 592-602.
101. Pulkkinen, M.; Pikkarainen, J.; Wirth, T.; Tarvainen, T.; Haapa-aho, V.; Korhonen, H.; Seppälä, J.; Järvinen, K. Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: formulation development and in vitro anticancer activity. Eur. J. Pharm. Biopharm., 2008, 70, 66-74.
102. Kim, M.J.; Lee, H.J.; Lee, I.A.; Kim, I.Y.; Lim, S.K.; Cho, H.A.; Kim, J.S. Preparation, of pH-sensitive, long-circulating and EGFR-targeted immunoliposomes. Arch. Pharm. Res., 2008, 31, 539-546.
103. Sharma, A.K.; Zhang, L.; Li, S.; Kelly, D.L.; Alakhov, V.Y.; Batrakova, E.V.; Kabanov, A.V. Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant. J. Control. Release, 2008, 131, 220-227.
104. Susa, M.; Iyer, A.K.; Ryu, K.; Choy, E.; Hornicek, F.J.; Mankin, H.; Milane, L.; Amiji, M.M.; Duan, Z. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One, 2010, 5, e10764.
105. Wu, J.; Lu, Y.; Lee, A.; Pan, X.; Yang, X.; Zhao, X.; Lee, R.J. Reversal of multidrug resistance by transferrin-conjugated liposomes coencapsulating doxorubicin and verapamil. J. Pharm. Pharm. Sci., 2007, 10, 350-357.
106. Song, X.R.; Zheng, Y.; He, G.; Yang, L.; Luo, Y.F.; He, Z.Y.; Li, S.Z.; Li, J.M.; Yu, S.; Luo, X.; Hou, S.X.; Wei, Y.Q. Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma. J. Pharm. Sci., 2010, 99, 4874-4879.
107. Patil, Y.; Sadhukha, T.; Ma, L.; Panyam, J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control. Release, 2009, 136, 21-29.
108. Pakunlu, R.I.; Wang, Y.; Saad, M.; Khandare, J.J.; Starovoytov, V.; Minko, T. In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug. J. Control. Release, 2006, 114, 153-162.
109. van Verklen, L.E.; Duan, Z.; Seiden, M.V.; Amiji, M.M. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res., 2007, 67, 4843-4850.
110. Wang, J.Q.; Tao, X.Y.; Zhang, Y.F.; Wei, D.Z.; Ren, Y.H. Reversion of multidrug resistance by tumor targeted delivery of antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles. Biomaterials, 2010, 31, 4426-4433.
111. Suzuki, S.; Inoue, K.; Hongoh, A.; Hashimoto, Y.; Yamazoe, Y. Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferrin receptor. B r. J. Cancer, 1997, 76, 83-89.
112. Mamot, C.; Drummond, D.C.; Hong, K.; Kirpotin, D.B.; Park, J.W. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist. Updat., 2003, 6, 271-279.
113. Matsuo, H.; Wakasugi, M.; Takanaga, H.; Ohtani, H.; Naito, M.; Tsuruo, T.; Sawada, Y. Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P-glycoprotein. J. Control. Release, 2001, 77, 77-86.
114. Milane, L.; Duan, Z.F.; Amiji, M. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol. Pharm., 2011, 8, 185-203.
115. Jin, Y.; Liu, S.J.; Yu, B.; Golan, S.; Koh, C.G.; Yang, J.T.; Huynh, L.; Yang, X.J.; Pang, J.X.; Muthusamy, N.; Chan, K.K.; Byrd, J.C.; Talmon, Y.; Lee, L.J.; Lee, R.J.; Marcucci, G. Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia. Mol. Pharm., 2010, 7, 196-206.
116. Lee, E.S.; Na, K.; Bae, Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Control. Release, 2005, 103, 405-418.